These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405 [TBL] [Abstract][Full Text] [Related]
3. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. Schellenbacher C; Roden R; Kirnbauer R J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991 [TBL] [Abstract][Full Text] [Related]
4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
5. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909 [TBL] [Abstract][Full Text] [Related]
6. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603 [TBL] [Abstract][Full Text] [Related]
7. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766 [TBL] [Abstract][Full Text] [Related]
9. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748 [TBL] [Abstract][Full Text] [Related]
17. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA Virol J; 2015 Sep; 12():140. PubMed ID: 26362430 [TBL] [Abstract][Full Text] [Related]
18. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Yoon SW; Lee TY; Kim SJ; Lee IH; Sung MH; Park JS; Poo H Vaccine; 2012 May; 30(22):3286-94. PubMed ID: 22426329 [TBL] [Abstract][Full Text] [Related]
19. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer. Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545 [TBL] [Abstract][Full Text] [Related]
20. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. Xu Y; Wang Q; Han Y; Song G; Xu X J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]